| 公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
| 2008 | The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells | Luqman, M.; Klabunde, S.; Lin, K.; Georgakis, G. V.; Cherukuri, A.; Holash, J.; Goldbeck, C.; Xu, X. M.; Kadel, E. E.; Lee, S. H.; Aukerman, S. L.; Jallal, B.; Aziz, N.; Wen-Kai Weng ; Wierda, W.; O'Brien, S.; Younes, A. | Blood | | | |
| 2005 | A non-internalizing anti-CD40 antibody, CHIR-12.12, blocks CD40L-induced cytokine production and mediates greater ADCC than rituximab in primary CLL cells | Tong, X.; Aukerman, S. L.; Lin, K.; Aziz, N.; Goldbeck, C.; Georgakis, G. V.; Younes, G.; Wen-Kai Weng ; O'Brien, S.; Wierda, W.; Jallal, B.; Luqman, M. | Blood | | | |
| 2015 | A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia | Strati, P.; Tong, W. G.; Vitale, C.; Wierda, W. G.; O'Brien, S.; Brown, J. R.; Wen-Kai Weng ; Kipps, T.; Keating, M. J.; Ferrajoli, A. | Leukemia & Lymphoma | | | |
